[1] BOOKMAN M A,BLESSING J A,HANJANI P,et al.Topotecan in squamous cell carcinoma of the cervix:a phase Ⅱ study of the gynecologic oncology group[J].Gynecol Oncol,2000,77(3):446-449.
[2] MUGGIA F M,BLESSING J A,METHOD M,et al.Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix:a gynecologic oncology group study[J].Gynecol Oncol,2004,92(2):639-643.
[3] MILLER D S,BLESSING J A,BODURKA D C,et al.Evaluation of pemetrexed(Alimta,LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix:a phase Ⅱ study of the gynecologic oncology group[J].Gynecol Oncol,2008,110(1):65-70.
[4] BORCOMAN E,Le TOURNEAU C.Keynote-158 study,FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer[J].Ann Transl Med,2020,8(23):1611.
[5] CHUNG H C,ROS W,DELORD J P,et al.Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer:results from the phase Ⅱ KEYNOTE-158 study[J].J Clin Oncol,2019,37(17):1470-1478.
[6] STREBHARDT K,ULLRICH A.Paul Ehrlich's magic bullet concept:100 years of progress[J].Nat Rev Cancer,2008,8(6):473-480.
[7] MATHE G,TRAN BA L O,BERNARD J.Effect on mouse leukemia 1210 of a combination by diazo-reaction of amethopterin and gamma-globulins from hamsters inoculated with such leukemia by heterografts[J].C R Hebd Seances Acad Sci,1958,246(10):1626-1628.
[8] GHOSE T,NORVELL S T,GUCLU A,et al.Immunochemotherapy of human malignant melanoma with chlorambucil-carrying antibody[J].Eur J Cancer(1965),1975,11(5):321-326.
[9] GHOSE T,NORVELL S T,GUCLU A,et al.Immunochemotherapy of malignant melanoma with chlorambucil-bound antimelanoma globulins:preliminary results in patients with disseminated disease[J].J Natl Cancer Inst,1977,58(4):845-852.
[10] MORRISON S L,JOHNSON M J,HERZENBERG L A,et al.Chimeric human antibody molecules:mouse antigen-binding domains with human constant region domains[J].Proc Natl Acad Sci U S A,1984,81(21):6851-6855.
[11] GROUP O M T S.A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants[J].N Engl J Med,1985,313(6):337-342.
[12] JONES P T,DEAR P H,FOOTE J,et al.Replacing the complementarity-determining regions in a human antibody with those from a mouse[J].Nature,1986,321(6069):522-525.
[13] van De VIJVER M J,PETERSE J L,MOOI W J,et al.Neu-protein overexpression in breast cancer.Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage Ⅱ breast cancer[J].N Engl J Med,1988,319(19):1239-1245.
[14] KIM K J,LI B,WINER J,et al.Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo[J].Nature,1993,362(6423):841-844.
[15] DUCRY L,STUMP B.Antibody-drug conjugates:linking cytotoxic payloads to monoclonal antibodies[J].Bioconjug Chem,2010,21(1):5-13.
[16] XU S.Internalization,trafficking,intracellular processing and actions of antibody-drug conjugates[J].Pharm Res,2015,32(11):3577-3583.
[17] 武刚，付志浩，徐刚领，等.抗体偶联药物研发进展[J].生物医学转化，2021(2)：1-11.
[18] MAHMOOD I.Clinical pharmacology of antibody-drug conjugates[J].Antibodies(Basel),2021,10(2):1-19.
[19] ALLEY S C,OKELEY N M,SENTER P D.Antibody-drug conjugates:targeted drug delivery for cancer[J].Curr Opin Chem Biol,2010,14(4):529-537.
[20] GRANSETH B,ODERMATT B,ROYLE S J,et al.Clathrin-mediated endocytosis:the physiological mechanism of vesicle retrieval at hippocampal synapses[J].J Physiol,2007,585(Pt 3):681-686.
[21] SMITH L M,NESTEROVA A,ALLEY S C,et al.Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97[J].Mol Cancer Ther,2006,5(6):1474-1482.
[22] JEDEMA I,BARGE R M,van Der VELDEN V H,et al.Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin:rationale for efficacy in CD33-negative malignancies with endocytic capacity[J].Leukemia,2004,18(2):316-325.
[23] LAW C L,CERVENY C G,GORDON K A,et al.Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates[J].Clin Cancer Res,2004,10(23):7842-7851.
[24] SCHRAMA D,REISFELD R A,BECKER J C.Antibody targeted drugs as cancer therapeutics[J].Nat Rev Drug Discov,2006,5(2):147-159.
[25] 何博，谭爱玲，胡文娟，等.浓缩血小板的制备和保存过程中血小板表面组织因子的表达[J].实用医学杂志，2021，8(37)：1055-1059.
[26] ZHAO X,CHENG C,GOU J,et al.Expression of tissue factor in human cervical carcinoma tissue[J].Exp Ther Med,2018,16(5):4075-4081.
[27] COLEMAN R L,LORUSSO D,GENNIGENS C,et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer(innovaTV 204/GOG-3023/ENGOT-cx6):a multicentre,open-label,single-arm,phase 2 study[J].Lancet Oncol,2021,22(5):609-619.
[28] LORUSSO D,VERGOTE I,O'CEARBHAILL R E,et al.Tisotumab vedotin(TV) + pembrolizumab(pembro) in first-line(1L) recurrent or metastatic cervical cancer(r/mCC):interim results of ENGOT Cx8/GOG 3024/innovaTV 205[J].Journal of Clinical Oncology,2022,40(16_suppl):5507.
[29] WANG J,DAY R,DONG Y,et al.Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers[J].Mol Cancer Ther,2008,7(2):280-285.
[30] STEPAN L P,TRUEBLOOD E S,HALE K,et al.Expression of Trop2 cell surface glycoprotein in normal and tumor tissues:potential implications as a cancer therapeutic target[J].J Histochem Cytochem,2011,59(7):701-710.
[31] TSUKAHARA Y,TANAKA M,MIYAJIMA A.TROP-2 expressed in the trunk of the ureteric duct regulates branching morphogenesis during kidney development[J].PLoS One,2011,6(12):e28607.
[32] ZEYBEK B,MANZANO A,BIANCHI A,et al.Cervical carcinomas that overexpress human trophoblast cell-surface marker(Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan[J].Sci Rep,2020,10(1):973.
[33] 齐丽敏,孙波,张学玲,等.hTERC、HER-2和c-myc基因在宫颈异常细胞中的表达及意义[J].实用医学杂志,2015,31(18):3021-3023.
[34] CHAVEA-BLANCO A,PEREZ-SANCHEZ V,GONZALEZ-FIERRO A,et al.HER2 expression in cervical cancer as a potential therapeutic target[J].BMC Cancer,2004,4:59.
[35] DIVER E J,FOSTER R,RUEDA B R,et al.The therapeutic challenge of targeting HER2 in endometrial cancer[J].Oncologist,2015,20(9):1058-1068.
[36] FORTMAN D,ISSA R,STANBERY L,et al.HER2-positive metastatic cervical cancer responsive to first and second-line treatment:a case report[J].Gynecol Oncol Rep,2020,31:100520.
[37] BUZA N.HER2 testing in endometrial serous carcinoma:time for standardized pathology practice to meet the clinical demand[J].Arch Pathol Lab Med,2021,145(6):687-691.
[38] HU X,ZHANG J,LIU R,et al.Updated results and biomarker analyses from the phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors[J].Journal of Clinical Oncology,2022,40(16_suppl):1037.
[39] ENDO Y,MOHAN N,DOKMANOVIC M,et al.Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities:a gateway to better understanding of ADC-associated toxicities[J].Antib Ther,2021,4(1):55-59.
[40] 中国抗癌协会肿瘤临床化疗专业委员会，中国药学会医院药学专业委员会.抗体偶联药物安全性跨学科管理中国专家共识[J].中国医院药学杂志，2023,43(1):1-10. |
